Elizabeth S. Eaton

Health and science reporter looking for next opportunity; Former @BioCentury writer

[Consort Partners PR @consortpartners]

The public launch of @devrev’s #DevCRM platform offers a new approach to managing SaaS customer management.

More insight from co-founders @dheeraj and @DevReveler in #CRMBuyer. https://t.co/1PW6XQhg1q

[Lily Blair @BlairLilyM]

Exceptionally excited to share this paper from D2G Oncology. Big thanks to @ianwinters90 @PetrovADmitri @labwinslow and the rest of the team at D2G. It’s been a really fun collaboration, thanks to @politikaterina @dow_lab @cellecta https://t.co/dP0ySnSt2f 1/n

[Galym Imanbayev @GalymImanbayev]

Truly seminal piece of work - in both implications on our understanding of cancer biology and the interdisciplinary methods by which we can interrogate it. Great job D2G Oncology team on advancing this work! #oncology #biotech

[Madhukar Kumar @madhukarkumar]

What a fitting end to the GA launch week, thanks to @Nasdaq @devrev

[stokols @stokols]

Follow @Boost_Infinite for direct access to Boost Infinite launch updates

[Ed Yong is not here @edyong209]

🚨🚨Here’s the big piece I’ve been promising: an Atlantic cover story about the US’s catastrophic mishandling of the pandemic. It’s a full autopsy of what went wrong, every unattended weakness & unheeded warning, every festering wound & reopened scar. 1/

https://t.co/568JBktc7M

[Elizabeth S. Eaton @LaboratoryLiz]

.@smwong419 explores neutralization data for Moderna's #COVID19 #vaccine -- the highest titers reported to date

[Jeff Cranmer @jeff_cranmer]

$MRNA, @NIH pick Phase 3 #COVID19 vaccine dose, beat $BNTX and $PFE with highest neutralizing titers to date via @BioCentury https://t.co/dIHnBG3Zwm

[Jeff Cranmer @jeff_cranmer]

As $ABBV continues to aggressively pursue ways to offset future generic competition for its top seller, Humira, the company's latest deal marks something of a course correction toward innovation after its $AGN takeout. via @LaboratoryLiz in @BioCentury https://t.co/NAoQ8zIuuU

[Jeff Cranmer @jeff_cranmer]

BREAKING: @DrWoodcockFDA stepping away as @US_fda CDER director to focus on #COVID19, Marks leaving Operation Warp Speed to focus on response w/in CBER. @steveusdin1 via @BioCentury https://t.co/z9Luwva1e0

[BioSig Technologies @BioSig_Tech]

FDA green-lights more than 70 #COVID19 trials via treatment acceleration program - @LaboratoryLiz via @BioCentury $BSGM #PharmaIndustry #MedicalResearch #Healthcare https://t.co/zU6BsMVJ1q

[Elizabeth S. Eaton @LaboratoryLiz]

A pair of deals this week (@Vir_Biotech+@generationbio and @neurimmune+@ethris_mRNA) are centered on emerging tech that could accelerate development of a #COVID19 therapy by turning a patient's body into an antibody manufacturer https://t.co/43OZnnWoAb

[Elizabeth S. Eaton @LaboratoryLiz]

The @BioCentury team is dedicated to covering the #COVID19 pandemic: The science of #SARSCoV2, therapeutic and vaccine development, policies coming out of Washington, and more. Check out our free content here: https://t.co/01gTaiILmu

[BioCentury @BioCentury]

Why @steveusdin1 says FDA's authorization of malaria drugs to treat #COVID19 was unwise. https://t.co/i837Fl115G

[Elizabeth S. Eaton @LaboratoryLiz]

Please donate if you can! @UCSF needs supplies to combat #COVID19 #coronavirus

[BioCentury @BioCentury]

.@UCSF is accepting donations of critical supplies for its frontline care providers in the Bay Area to combat the #COVID19 outbreak, including protective equipment & sanitizing items. Donation sites at three locations. Please help if you can https://t.co/RCI83oTlsN

[Elizabeth S. Eaton @LaboratoryLiz]

@brandonnadig Make your own sourdough starter! I’ve coped with self isolation by baking three loaves in the past week 💪

[Elizabeth S. Eaton @LaboratoryLiz]

.@GileadSciences CEO O’Day says patients will be focus of its #2019nCoV response, not patents

[Jeff Cranmer @jeff_cranmer]

$GILD O'Day reacts to Chinese institutes seeking to patent remdesivir for #2019nCov: 'We will not get in a patent dispute.' via @LaboratoryLiz @li_hongjiang in @BioCentury https://t.co/zbwnnYjEuy

[Elizabeth S. Eaton @LaboratoryLiz]

@GileadSciences @WHO And here's our table tallying ongoing trials of therapeutics to treat #2019nCoV #coronavirus https://t.co/az9DZ71ZyW

[Elizabeth S. Eaton @LaboratoryLiz]

A newsy couple of days for @GileadSciences and its antiviral to treat #coronavirus:
1. #remdesivir almost completely resolves symptoms of U.S. patient
2. $GILD plans to enroll patients in 2 Chinese trials mid-Feb
https://t.co/0ZCNVfwp0g

[Elizabeth S. Eaton @LaboratoryLiz]

@GileadSciences 3. Gilead says it's "investing pretty heavily" and working “night and day” to ramp up manufacturing for #remdesivir
4. @WHO says #remdesivir is the most promising candidate to treat #2019nCoV https://t.co/v5WDhyCh83

[steve usdin @steveusdin1]

Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://t.co/RlCwaMQuyU.
Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. https://t.co/RlCwaMQuyU
All BioCentury coverage of the outbreak is in front of the paywall at https://t.co/VgXbI4OMQB.